🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Qutenza 179 mg cutaneous patch, CAPSAICIN, Qutenza 179 mg cutaneous patch

    Lacuna Pharma Pty Ltd

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial

  2. RAD001

    Novartis Pharmaceuticals

    Tuberous Sclerosis Complex-associated Refractory Seizures

    phase 3 small molecule completed

    1 trial

  3. RANOLAZINE, FLECARDIA Διάλυμα για ένεση/έχχυση

    Lacuna Pharma Pty Ltd

    Restoration of sinus rhythm in patients with recent AF onset

    phase 3 small molecule active

    1 trial

  4. RAPIBLOC 300 mg, poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  5. REC-2282

    RECURSION PHARMACEUTICALS, INC.

    Neurofibromatosis Type 2

    phase 3 small molecule terminated

    1 trial

  6. REGN4461 - Mibavademab

    Lacuna Pharma Pty Ltd

    Monogenic obesity

    phase 3 small molecule active

    1 trial

  7. REGN7508, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, Eliquis 2.5 mg film-coated tablets, SODIUM CHLORIDE, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 3 small molecule active

    1 trial

  8. REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion, NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  9. RHB-102

    RedHill Biopharma

    Gastroenteritis

    phase 3 small molecule completed

    1 trial

  10. RHB-104

    RedHill Biopharma

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  11. RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

    RedHill Biopharma

    Crohn Disease

    phase 3 small molecule completed

    1 trial

  12. RHB-105

    RedHill Biopharma

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  13. RHB-105

    RedHill Biopharma

    Dyspepsia

    phase 3 small molecule completed

    1 trial

  14. RHB-204

    RedHill Biopharma

    Pulmonary Mycobacterium Avium Complex Infection

    phase 3 small molecule terminated

    1 trial

  15. RITUXIMAB, Capsule, hard, Calquence 100 mg hard capsules, BENDAMUSTINE

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  16. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  17. RO7496998

    Atea Pharmaceuticals

    COVID-19

    phase 3 small molecule terminated

    1 trial

  18. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  19. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  20. Ramosetron

    Astellas Pharma Inc

    Vomiting

    phase 3 small molecule completed

    1 trial

  21. Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial

  22. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    1 trial

  23. Ranibizumab

    Novartis Pharmaceuticals

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial

  24. Ranibizumab 0.5 mg

    Novartis Pharmaceuticals

    Central Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources